BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34697060)

  • 1. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.
    Cunningham JM; Winham SJ; Wang C; Weiglt B; Fu Z; Armasu SM; McCauley BM; Brand AH; Chiew YE; Elishaev E; Gourley C; Kennedy CJ; Laslavic A; Lester J; Piskorz A; Sekowska M; Brenton JD; Churchman M; DeFazio A; Drapkin R; Elias KM; Huntsman DG; Karlan BY; Köbel M; Konner J; Lawrenson K; Papaemmanuil E; Bolton KL; Modugno F; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):132-141. PubMed ID: 34697060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 5. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
    Kuroda T; Kohno T
    Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis.
    Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N
    Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
    Cicek MS; Koestler DC; Fridley BL; Kalli KR; Armasu SM; Larson MC; Wang C; Winham SJ; Vierkant RA; Rider DN; Block MS; Klotzle B; Konecny G; Winterhoff BJ; Hamidi H; Shridhar V; Fan JB; Visscher DW; Olson JE; Hartmann LC; Bibikova M; Chien J; Cunningham JM; Goode EL
    Hum Mol Genet; 2013 Aug; 22(15):3038-47. PubMed ID: 23571109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
    Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
    Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
    Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
    Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
    Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
    Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
    Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
    Su YF; Tsai EM; Chen CC; Wu CC; Er TK
    Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
    EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.